U.S. markets close in 5 hours 46 minutes
  • S&P 500

    4,683.86
    +92.19 (+2.01%)
     
  • Dow 30

    35,754.76
    +527.73 (+1.50%)
     
  • Nasdaq

    15,653.46
    +428.31 (+2.81%)
     
  • Russell 2000

    2,257.84
    +54.36 (+2.47%)
     
  • Crude Oil

    71.95
    +2.46 (+3.54%)
     
  • Gold

    1,781.90
    +2.40 (+0.13%)
     
  • Silver

    22.39
    +0.12 (+0.55%)
     
  • EUR/USD

    1.1249
    -0.0038 (-0.34%)
     
  • 10-Yr Bond

    1.4530
    +0.0190 (+1.32%)
     
  • GBP/USD

    1.3242
    -0.0019 (-0.14%)
     
  • USD/JPY

    113.6100
    +0.1200 (+0.11%)
     
  • BTC-USD

    51,617.20
    +3,201.30 (+6.61%)
     
  • CMC Crypto 200

    1,332.54
    +11.26 (+0.85%)
     
  • FTSE 100

    7,335.73
    +103.45 (+1.43%)
     
  • Nikkei 225

    28,455.60
    +528.23 (+1.89%)
     

Edesa Biotech to Join Panel Discussion at Industry Event

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

TORONTO, ON / ACCESSWIRE / May 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event organized by the Ontario Bioscience Innovation Organization. As part of a panel of health science and investment professionals, Dr. Nijhawan is expected to discuss publicly available information regarding Edesa and its corporate strategy.

The panel discussion, which is titled "Health Science IPOs: Will We Continue To Break Records?" is scheduled to take place on Tuesday, June 1, 2021 at 12:00 PM Eastern Time. More information is available at the event website.

About Edesa Biotech, Inc.

Edesa Biotech, Inc. (Nasdaq:EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that we are developing as a treatment for Acute Respiratory Distress Syndrome (ARDS). ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. By targeting sPLA2 with enzyme inhibitors - at the inception of inflammation rather than after inflammation has occurred - Edesa believes that drugs based on this technology could provide a powerful anti-inflammatory therapeutic strategy for treating diverse inflammatory/allergic conditions. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California. Sign up for news alerts.

Edesa Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as COVID-19. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.

Contact:
Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
investors@edesabiotech.com

SOURCE: Edesa Biotech



View source version on accesswire.com:
https://www.accesswire.com/649442/Edesa-Biotech-to-Join-Panel-Discussion-at-Industry-Event